Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2013

Open Access 01-12-2013 | Research

Long-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinoma

Authors: Klaus-Jürgen Winzer, Joachim Bellach, Peter Hufnagl

Published in: Diagnostic Pathology | Issue 1/2013

Login to get access

Abstract

Background

Apart from a number of cases of inaccurate prognosis in regard to individual patients, the inter- and intra-observer variability of the classical, histological prognosis parameters have been under repeated discussion. For this reason, a long-term analysis was carried out in regard to overall survival by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) to objectify tumour grading in the case of breast carcinoma.
This consists of a selective representation of argyrophilic proteins that are associated with the nucleolus organising regions.

Methods

The evaluation included 244 female patients with an average age of 59.3 years. The characterisation of the histological sections was carried out on the basis of the AMBA/R system. With this software the histometric characterisation level was evaluated in terms of the nucleolus organizer regions. The post-observation data were obtained from the clinical register and were complemented by mortality data from the cancer registers and by data supplied by the residents’ registration office of Berlin.

Results

The average post-observation period was 106.6 months. With the Cox-Regression the influence of the co-variables (conventional prognosis parameters and AgNOR parameters) were examined. In the model, only the parameters pN, G and various AgNOR parameters remain present.

Conclusion

There is a strong correlation between survival and selected AgNOR parameters. These could replace the conventional grading as the standard measure for the mitosis rate together with the pleomorphism level. Instead of the-time consuming AMBA/R system originally used, a new implementation of AgNOR quantification with modern VM systems could be applied.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1449591192859058​.
Appendix
Available only for authorised users
Literature
1.
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20: 1319-1329.PubMedCentralCrossRefPubMed
2.
Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H: Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. Biomed Biochim Acta. 1991, 50: 731-741.PubMed
3.
Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C: Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2011, 11: 617-634.CrossRefPubMed
4.
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE, Wickerham DL, Wolmark N: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor–positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010, 28: 1677-1683.PubMedCentralCrossRefPubMed
5.
van't Veer LJ, Paik S, Hayes DF: Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005, 23: 1631-1635.CrossRefPubMed
6.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M, EP Investigators: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011, 17: 6012-6020.CrossRefPubMed
7.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752.CrossRefPubMed
8.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members: Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011, 22: 1736-1747.PubMedCentralCrossRefPubMed
9.
10.
Elzagheid A, Kuopio T, Pyrhönen S, Collan Y: Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?. Diagn Pathol. 2006, 1: 41-PubMedCentralCrossRefPubMed
11.
Zhang Q, Zhang Q, Cong H, Zhang X: The ectopic expression of BRCA1 is associated with genesis, progression, and prognosis of breast cancer in young patients. Diagn Pathol. 2012, 7: 181-PubMedCentralCrossRefPubMed
12.
dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrão EI: Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol. 2012, 7: 104-PubMedCentralCrossRefPubMed
13.
MariadelasMercedes N, Fernando P, Florencia P, Néstor L, Hugo K, Silvana N, Alejandro G, Alejandra A, Boris E, Denninghoff VC, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET): Immunohistochemical characterization of neoplastic cells of breast origin. Diagn Pathol. 2012, 7: 73-CrossRef
14.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007, 25: 118-145.CrossRefPubMed
15.
Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G: Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 2011, 126: 109-117.CrossRefPubMed
16.
Hiroaki N, Kelly BD, Padilla M, Nikolaus W, Brunhoeber P, Bai I, Singh S, Ranger-Moore J, Bieniarz C, Hitoshi T, Grogan TM: A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012, 7: 60-CrossRef
17.
Guski H, Hufnagl P, Freitag A, Winzer K-J: Automatisierte Mikroskopbildanalyse und Prognose von Präneoplasien und Karzinomen der Brustdrüse. Gegenbaur's morphol Jahrb. 1989, 135: 39-53.
18.
Guski H, Winzer K-J, Hufnagl P, Wolf G, Reichert S: Automated grading in breast cancer by image analysis of histological sections. Acta Stereol. 1990, 9: 259-270.
19.
Guski H, Winzer K-J, Seidenfaden U, Hufnagl P, Wolf G: Häufigkeitsverteilung, mikroskopische Bildanalyse und Grading des Mammakarzinoms. Zentralbl Pathol. 1991, 137: 249-255.PubMed
20.
Guski H, Hufnagl P, Kaufmann O, Krause K, Winzer KJ: AgNOR Analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast. Anal Quant Cytol Histol. 2000, 22: 206-212.PubMed
21.
Günther L, Hufnagl P, Winzer K-J, Guski H: Different proliferation patterns in breast cancer: AgNOR measurements in ER-negative and ER-positive tumor cells. Anal Cell Pathol. 2000, 20: 155-162.CrossRefPubMed
22.
Hufnagl P, Guski H, Schulz HJ: Measuring of AgNORs using image analysis. Zentralbl Pathol. 1994, 140: 31-35.PubMed
23.
Günther L, Hufnagl P: Technique and feasibility of a dual staining method for estrogen receptors and AgNORs. Anal Cell Pathol. 2000, 20: 151-154.CrossRefPubMed
24.
Hufnagl P, Wenzelides K: Methoden der Charakterisierung histologischer Schnittpräparate auf der Basis des AMBA/R-Systems. Gegenbaurs Morphol Jahrb. 1989, 135: 33-38.PubMed
25.
Hufnagl P, Beil M, Wenzelides K, Martin H: Die Vermessung der Anzahl, Größe und Lage von AgNORs in histologischen Schnitten von Astrozytomen. Zentralbl Pathol. 1991, 137: 493-497.PubMed
26.
Winzer K-J, Bellach J: Wertigkeit der routinemäßig erfassten Nachsorgedaten bei Brustkrebspatientinnen. Zentbl Chir. 2010, 153: 257-261.CrossRef
27.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410.CrossRefPubMed
28.
Abboud P, Lorenzato M, Joly D, Quereux C, Birembaut P, Ploton D: Prognostic value of a proliferation index including MIB1 and argyrophilic nucleolar organizer regions proteins in node-negative breast cancer. Am J Obstet Gynecol. 2008, 199: 1-7.CrossRef
29.
Bánkfalvi A, Giuffrè G, Ofner D, Diallo R, Poremba C, Buchwalow IB, Barresi V, Böcker W, Tuccari G: Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis. Int J Oncol. 2003, 23: 1285-1292.PubMed
30.
Ceccarelli C, Trerè D, Santini D, Taffurelli M, Chieco P, Derenzini M: AgNORs in breast tumours. Micron. 2000, 31: 143-149.CrossRefPubMed
31.
Kesari AL, Chellam VG, Nair PP, Madhavan J, Nair P, Nair MK, Pillai MR: Tumor proliferative fraction in infiltrating duct carcinoma. Gen Diagn Pathol. 1997, 143: 219-224.PubMed
32.
Sinha SK, Singh UR, Bhatia A, Gupta S: Cytomorphological features, AgNOR counts and c-erb B-2 in carcinoma breast. J Indian Med Assoc. 1998, 96: 71-76.PubMed
33.
Krüger S, Fahrenkrog T, Müller H: Proliferative and apoptotic activity in lobular breast carcinoma. Int J Mol Med. 1999, 4: 171-174.PubMed
34.
Treré D, Ceccarelli C, Montanaro L, Tosti E, Derenzini M: Nucleolar size and activity are related to pRb and p53 status in human breast cancer. Anonymous. J Histochem Cytochem. 2004, 52: 1601-1607.CrossRefPubMed
35.
Treré D, Ceccarelli C, Migaldi M, Santini D, Taffurelli M, Tosti E, Chieco P, Derenzini M: Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients. Appl Immunohistochem Mol Morphol. 2006, 14: 314-323.CrossRefPubMed
Metadata
Title
Long-term analysis to objectify the tumour grading by means of automated microscopic image analysis of the nucleolar organizer regions (AgNORs) in the case of breast carcinoma
Authors
Klaus-Jürgen Winzer
Joachim Bellach
Peter Hufnagl
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2013
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-8-56

Other articles of this Issue 1/2013

Diagnostic Pathology 1/2013 Go to the issue

Research

Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis

Case Report

Sudden, unexpected death due to glioblastoma: report of three fatal cases and review of the literature

Research

De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression

Research

The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer

Research

Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases −2 expression in ovarian carcinoma

Research

RETRACTED ARTICLE: Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells